800.90
+2.86%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Albert David
Its shares trade on NSE under the ticker ALBERTDAVD.NS. It has been listed since 14 June 2016. In the fiscal year to 31 March 2025, it reported revenue of ₹3.46bn and net income of ₹172.0m. At that date it held total assets of ₹5.11bn and shareholders' equity of ₹3.92bn.
Albert David Ltd. engages in the manufacturing and trade of pharmaceuticals. The company is headquartered in Kolkata, West Bengal. The company went IPO on 2016-06-14. The firm offers its products under various categories, which includes parenteral, oral/enteral, topical agents and vision care. Its parenteral consists of amino acids infusion, antimicrobial, anti-leishmaniasis (kalazar), hemostat, neurotropic vitamin, and placenta extract. Its oral/enteral consists of amino acids oral, anthelmintic, anti-microbial, anti ulcerants, anti-vertigo, appetite stimulants, anti-tubercular, hematinic, oral vitamin b complex and expectorant / cough syrup. Its topical agents consist of non-steroidal anti-inflammatory drugs (NSAID). Its vision care consists of anti-glaucoma, anti-infective, tear substitutes and anti-infective with NSAID. The company has presence in Southeast Asia, Africa, countries of Middle - East, Europe, United States of America, and Latin America.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 Jun 2016
- Employees
- 1,271
- Website
- albertdavidindia.com ↗
Leadership
Pay as last reported
- Shri. Arun KothariExecutive Chairman of the Board, since 2008₹17.8m
- Mr. Umesh KunteChief Executive Officer, Managing Director
- Mr. Ranadeep BhattacharyaChief Financial Officer
- Mr. Lalit LohiaChief Compliance Officer, Company Secretary
- Mr. S. BhattacharyaPlant Head, Kolkata
- Mr. A. J. ChattopadhyayCorporate Head – Human Resources
- Mr. Anirban GhoshHead of Sales & Marketing
- Mr. Ashis MajumdarHead of Sales & Marketing
- Mr. H. T. NazarePlant Head, Ghaziabad
- Mr. Anand KothariNon-Executive Director
- Smt. Prabhawati KothariNon-Executive Director₹160,000
- Dr. Rajiv DesaiNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Albert David Ltd. manufactures parenteral products like amino acids infusion and antimicrobial drugs.
- The company offers oral/enteral products including anti-ulcerants and anti-tubercular medications.
- Albert David Ltd. has a global presence in Southeast Asia, Africa, and the United States.
Weaknesses
- The company's product portfolio lacks a significant focus on innovative biologics or gene therapies.
- Albert David Ltd. does not have a strong presence in the European market compared to other regions.
- The firm's product range does not include advanced ophthalmic solutions beyond basic vision care.
Opportunities
- Expanding into the growing Middle East pharmaceutical market could increase market share.
- The demand for anti-leishmaniasis drugs in Africa presents a significant opportunity.
- Increasing global demand for oral vitamin B complex products offers growth potential.
Threats
- Competition from established pharmaceutical companies in the United States poses a threat.
- Rising raw material costs in the European market could impact profitability.
- Regulatory changes in the United States may affect product approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.